CA Manthous, JB Hall, D Olson, M Singh, W Chatila, A Pohlman, R Kushner, GA Schmidt and LD Wood
Department of Medicine, University of Chicago, Illinois 60637.

Hyperthermic critically ill patients are commonly cooled to reduce their oxygen consumption (VO2). However, no previous studies in febrile humans have measured VO2 during cooling. We cooled 12 febrile, critically ill, mechanically ventilated patients while measuring VO2 and CO2 production (VCO2) by analysis of inspired and expired gases. All patients were mechanically ventilated for hypoxemic, hypercapneic, or shock-related respiratory failure and had a mean APACHE II score of 22.4 +/- 7.7. As temperature was reduced from 39.4 +/- 0.8 to 37.0 +/- 0.5 degrees C, VO2 decreased from 359.0 +/- 65.0 to 295.1 +/- 57.3 ml/min (p < 0.01) and VCO2 decreased from 303.6 +/- 43.6 to 243.5 +/- 37.3 ml/min (p < 0.01). The respiratory quotient (RQ) did not change significantly, and calculated energy expenditure decreased from 2,481 +/- 426 to 1,990 +/- 33 kcal/day (p < 0.01). In 7 patients with right heart catheters, cardiac output decreased from 8.4 +/- 3.2 to 6.5 +/- 1.8 L/min (p < 0.01) as the oxygen extraction fraction also tended to decrease from a mean of 28.2 +/- 6.8 to 23.4 +/- 4.7% (p = 0.12) during cooling. Accordingly, cooling the febrile patient unloads the cardiorespiratory system and, in situations of limited oxygen delivery or hypoxemic respiratory failure, may thus facilitate resuscitation and minimize the potential for hypoxic tissue injury.

This article has been cited by other articles:

				K. S. Kapitan Teaching pulmonary gas exchange physiology using computer modeling Advan Physiol Educ, March 1, 2008; 32(1): 61 - 64. [Abstract] [Full Text] [PDF]

				E. P. Rivers, L. McIntyre, D. C. Morro, and K. K. Rivers Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity Can. Med. Assoc. J., October 25, 2005; 173(9): 1054 - 1065. [Abstract] [Full Text] [PDF]

				F. Stephan, S. Ghiglione, F. Decailliot, L. Yakhou, P. Duvaldestin, and P. Legrand Effect of excessive environmental heat on core temperature in critically ill patients. An observational study during the 2003 European heat wave Br. J. Anaesth., January 1, 2005; 94(1): 39 - 45. [Abstract] [Full Text] [PDF]

				R. Rokyta Jr, M. Matejovic, A. Krouzecky, K. Opatrny Jr, J. Ruzicka, and I. Novak Effects of continuous venovenous haemofiltration-induced cooling on global haemodynamics, splanchnic oxygen and energy balance in critically ill patients Nephrol. Dial. Transplant., March 1, 2004; 19(3): 623 - 630. [Abstract] [Full Text] [PDF]

				T. S. Walsh Recent advances in gas exchange measurement in intensive care patients Br. J. Anaesth., July 1, 2003; 91(1): 120 - 131. [Full Text] [PDF]

				M. Sakoh and A. Gjedde Neuroprotection in hypothermia linked to redistribution of oxygen in brain Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H17 - H25. [Abstract] [Full Text] [PDF]

				D. C. Gore, D. Chinkes, A. Sanford, D. W. Hart, S. E. Wolf, and D. N. Herndon Influence of Fever on the Hypermetabolic Response in Burn-Injured Children Arch Surg, February 1, 2003; 138(2): 169 - 174. [Abstract] [Full Text] [PDF]

				V. Gozzoli, P. Schottker, P. M. Suter, and B. Ricou Is It Worth Treating Fever in Intensive Care Unit Patients?: Preliminary Results From a Randomized Trial of the Effect of External Cooling Arch Intern Med, January 8, 2001; 161(1): 121 - 123. [Abstract] [Full Text] [PDF]

				P. E. Marik Fever in the ICU Chest, March 1, 2000; 117(3): 855 - 869. [Abstract] [Full Text] [PDF]

				K. I. Plaisance and P. A. Mackowiak Antipyretic Therapy: Physiologic Rationale, Diagnostic Implications, and Clinical Consequences Arch Intern Med, February 28, 2000; 160(4): 449 - 456. [Abstract] [Full Text] [PDF]

				Q. Jiang, L. DeTolla, N. van Rooijen, I. S. Singh, B. Fitzgerald, M. M. Lipsky, A. S. Kane, A. S. Cross, and J. D. Hasday Febrile-Range Temperature Modifies Early Systemic Tumor Necrosis Factor Alpha Expression in Mice Challenged with Bacterial Endotoxin Infect. Immun., April 1, 1999; 67(4): 1539 - 1546. [Abstract] [Full Text] [PDF]

				P. A. MACKOWIAK and K. I. PLAISACNE Benefits and Risks of Antipyretic Therapy Ann. N.Y. Acad. Sci., September 29, 1998; 856(1): 214 - 223. [Abstract] [Full Text] [PDF]